Article Text

Download PDFPDF
Original article
Impact of peroral cholangioscopy on the management of indeterminate biliary conditions: a multicentre prospective trial
  1. Frederic Prat1,
  2. Sarah Leblanc1,
  3. Frantz Foissac2,
  4. Thierry Ponchon3,
  5. René Laugier4,
  6. Philippe Bichard5,6,
  7. Frédérique Maire7,
  8. Dimitri Coumaros8,
  9. Antoine Charachon9,
  10. Bruno Vedrenne10,
  11. Isabelle Boytchev11,
  12. Stanislas Chaussade12,
  13. Nadira Kaddour13,
  14. Arthur Laquière14,
  15. Sèbastien Gaujoux15
  1. 1 Department of Gastroenterology, Assistance Publique Hopitaux de Paris, Paris-Descartes University, Paris, France
  2. 2 Clinical Research Unit, Cochin Hospital, Paris, France
  3. 3 Gastroenterology, Hopital Edouard Herriot, Lyon, France
  4. 4 Gastroenterology, Assistance Publique Hopitaux de Marseille, Marseille, France
  5. 5 Digestive Endoscopy Unit, Centre Hospitalier Universitaire de Grenoble, Grenoble, France
  6. 6 Service de Gastro-entérologie et Hépatologie, Hopitaux Universitaires de Geneve, Geneva, Switzerland
  7. 7 Gastroenterology, Hopital Beaujon, Clichy, France
  8. 8 IRCAD/EITS, University Hospital, Strasbourg, France
  9. 9 Endoscopy, Fondation Princesse Grace de Monaco, Monaco, Monaco
  10. 10 Groupe Hospitalier de la Region de Mulhouse et Sud Alsace, Mulhouse, France
  11. 11 Hopital Bicetre, Le Kremlin-Bicetre, France
  12. 12 Gastroenterology, Assistance Publique Hopitaux de Paris, Paris, France
  13. 13 Clinical Research Unit, Hopital Cochin, Paris, France
  14. 14 Gastroenterology and Endoscopy Unit, Hopital st joseph, Marseille, France
  15. 15 Department of Surgery, Assistance Publique - Hopitaux de Paris, Paris, France
  1. Correspondence to Professor Frederic Prat, Endoscopy Unit, Hôpital Cochin, Paris 75014, France; frederic.prat{at}


Background and aims Single-operator cholangioscopy (SOC) can help diagnose biliopancreatic conditions. The impact of SOC on patient outcome has never been specifically addressed.

Patients and methods Consecutive patients bearing indeterminate biliary strictures (IDBS), or primary sclerosing cholangitis (PSC) with suspected cholangiocarcinoma, were included. Patients with IDBS had at least one previous inconclusive endoscopic retrograde cholangio pancreatography (ERCP) + cytology. Primary endpoint was the difference in adequacy of management planned before and after SOC with regard to final diagnosis obtained after surgery or 24 months follow-up.

Design Prospective open-label multicentre trial.

Results 61 patients were included (IDBS: 48; PSC: 13); 70.5% had a benign lesion (IDBS 66.7%, PSC 84.6%). The management adequacy rate was significantly higher after SOC than before SOC overall (p<10–5), in IDBS (p<0.001) and PSC (p<0.05) patients. SOC induced changes in the management of the majority of patients in all groups (60.3%). The overall sensitivity of combined visual impression and biopsy ranged from 52% to 63.6% depending on investigator or independent expert rating (κ 0.92–0.96), whereas specificity, positive and negative predictive values of SOC were, respectively, 100%, 100% and 83.6%. Patient management observed at the end of follow-up was consistent with that anticipated after SOC in 88.5% overall.

Conclusion Despite a moderate sensitivity for the diagnosis of malignancy, SOC has a dramatic impact on the management of patients with IDBS and PSC with suspected carcinoma. Cholangioscopy might be implemented in the workup of selected patients with challenging diagnosis, when a significant impact on outcome (essentially resection vs conservative management) is to be expected.

  • biliary strictures
  • primary sclerosing cholangitis
  • endoscopic procedures
  • pancreatic tumours
  • endoscopic retrograde pancreatography

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors FP designed and planned the study, contributed patients and data analysis, wrote and submitted the study. SL contributed patients and analysed data. FF was the methodologist and statistician for the study. TP, RéL, PB, FééM, DC, AC, BV and IB contributed patients. SC formalised the idea of a multi-centre prospective study of SOC. NK monitored patient inclusion and study quality. AL and SG played the role of external independent reviewers with regard to patient outcome classification.

  • Funding The study was funded through a grant from the National Cancer Institute (INCA).

  • Competing interests FP, RL and TP have received consultancy fees from Boston Scientific before, during or after the study.

  • Patient consent Obtained.

  • Ethics approval IRB approval from CPP Ile de France-III under N°Am5042-2-S.C.2564 and registered under EUDRACT N°2008-A00672-53.

  • Provenance and peer review Not commissioned; externally peer reviewed.